MEDTECH REVIEWS: NON-INVASIVE ELECTROMAGNETIC THERAPIES (Part 1)
In 1979, The Food and Drug Administration 1979 approved PEMF Therapy for the healing of nonunion fractures . Electrical stimulation of the spine (as part of spinal fusion procedures) for failed fusions and congenital pseudarthroses. In October 2008 the Food and Drug Administration approved the use of PEMF therapy for treatment of major depressive disorder in PD patients who failed to achieve satisfactory improvement from very high dosages of antidepressant medications .
Clinical research has also been highly dedicated towards mental health. In 2006, the FDA approved PEMF Therapy for treatment of depression and anxiety. [7-9] Further reports have presented an est. 30% of depression cases have a resistance to antidepressant drugs, where Repetitive Transcranial Magnetic Stimulation (rTMS) and the application of Transcranially applied Pulsed Electromagnetic Fields (T-PEMF) has shown positive results in combination with antidepressants in patients with treatment-resistant depression.[11-12]
PEMF: HISTORY & EXPANSION OF MODERN TARGET ISSUES
Claims of electricity induction in aiding bone repair has been reported as far back as the mid 1800's, but it wasn't until the mid-1950's to the '70's that the scientific community significantly advanced its research toward the treatment of delated fractures in Western Europe and the US. Recent reviews have shown benefits of PEMF to include: neurological disorders, vascular disease, lung disorders, GI (gastrointenstinal) disease, rheumatic disease, dermatological issues, inflammation, tumors and immunological issues for both humans and animals. Clinical research studies have reported benefits for a host of specific issues including: musculoskeletal(MSK) Pain , bacteria and parasites, OstheoArthritis, mental health disorders (Depression), Multiple Sclerosis[16-17], Cancer and Alzheimer's Disease .
TMS and PEMF USE IN PARKINSON'S DISEASE
Parkinson’s disease (PD) is one of the most common progressive nervous system disorders that affects movement. It is a neurodegenerative disorder second only to Alzheimer’s disease, accompanied by the impairment of the cortico-subcortical excitation and inhibition systems, hence belonging to the involuntary movement diseases. In the first PD patients treated with high-frequency TMS in 1993, motor symptoms, tremor, rigidity and akinesia improved significantly allowing to decrease the administration of l-dopa by a mean of 55% .
VIEWPOINTS from the Healthcare Community
It is refreshing to learn about other forward thinking modalities and innovations in the healthcare field. These Innovations like pulsed electromagnetic field therapy(PEMF) and transcranial magnetic stimulation (TMS) are technologies that utilize non-invasive electromagnetic stimulation of cellular metabolic processes within various places in our body. The endgame of the technologies is for diagnostic information and therapeutic intervention of systemic disease. PEMF and TMS have proven that electromagnetic fields can provide non-invasive methods to diagnose and treat health concerns such as depression, pain, MS, Cancer, Alzheimer’s Disease, Parkinson’s Disease, healing responses, and Overall cardiovascular anomalies. This is so exciting because we can use this technology two recognize early metabolic and possibly genetic changes that could lead to accelerated aging disease and death. Also, we can use this technology as an intervention to the changes and correct the path of health. Both of these technologies have shown efficacy ( FDA approval) and promise ( more research is being done). There is no question that LESS IS MORE! That is if we recognize pathological conditions early and can correct them with little or no pharmacological or surgical intervention; “everybody wins!”
- By Randall Weisel DDS,MPS (www.laserhygienics.com)